209 filings
8-K
TLPH
Talphera Inc.
6 Mar 24
Talphera Announces Fourth Quarter 2023 Financial Results and Provides Corporate Update
4:11pm
8-K
TLPH
Talphera Inc.
1 Mar 24
Talphera Announces Reduction in Size of its Board of Directors from Ten to Seven Members
7:35am
8-K
TLPH
Talphera Inc.
22 Jan 24
Talphera Announces $26 Million Capital Commitment Through a Combination of a Non-Dilutive Royalty Monetization and Equity Offering
5:12pm
8-K
TLPH
Talphera Inc.
18 Jan 24
Entry into a Material Definitive Agreement
8:35am
8-K
TLPH
Talphera Inc.
9 Jan 24
Talphera will begin trading on Nasdaq under the trading symbol “TLPH” effective January 10
9:17am
8-K
5vzmt0ym
8 Nov 23
AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:14pm
8-K
w775qha86 fe
20 Oct 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:30pm
8-K
662pkz5ye lsxoya
10 Oct 23
Departure of Directors or Certain Officers
4:17pm
8-K
em50egh6 rte5oc
5 Oct 23
Changes in Registrant's Certifying Accountant
4:30pm
8-K
qjmgv
22 Sep 23
Other Events
5:18pm
8-K
ebvwzbtk7v2q6piwp8q1
10 Aug 23
AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:10pm
8-K
s3usjf8z4a0e injb
31 Jul 23
Other Events
9:47pm
8-K
zy6anwwjff5 bd44
21 Jul 23
Entry into a Material Definitive Agreement
8:15am
8-K
8petskvj5f1f
15 Jun 23
Other Events
4:06pm
8-K
goe5999fwt2x cxd
10 May 23
AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:11pm
8-K
b45h4byqp5cwckao39
28 Apr 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:06pm
8-K
b861 heiaouq
7 Apr 23
AcelRx Pharmaceuticals Announces Closing of Divestment of DSUVIA® to Alora Pharmaceuticals
3:37pm
8-K
xo95sd3eli 1yazi6nz
30 Mar 23
AcelRx Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results and Provides Corporate Update
4:10pm
8-K
7qumn elf
16 Mar 23
Entry into a Material Definitive Agreement
4:15pm
8-K
ap40zc5 6pdewppx75
29 Dec 22
Other Events
6:03am